📊 BFNH Key Takeaways
Is Bioforce Nanosciences Holdings, Inc.. (BFNH) a Good Investment?
BFNH exhibits severe financial distress with negative stockholders' equity of -$499.9K, indicating the company is technically insolvent. The company generated only $17.8K in revenue against $1.2M in net losses, demonstrating a fundamentally broken business model with no viable path to profitability. Negative operating cash flow and zero insider confidence complete a picture of a company in existential crisis.
The fundamentals indicate an extremely distressed business with negligible revenue, deeply negative operating economics, and persistent cash burn. Financial health is critically weak, with only $784 of cash, a near-zero liquidity position, and negative equity, leaving little evidence of sustainable operations or growth quality.
Why Buy Bioforce Nanosciences Holdings, Inc.. Stock? BFNH Key Strengths
- Minimal cash burn relative to asset base in current period
- Positive gross margin of 24.5% indicates some pricing power on limited sales
- Laboratory analytical instruments sector has legitimate long-term demand
- The company is still generating some revenue, indicating limited ongoing commercial activity
- Gross profit is positive, showing the core product/service is not completely uneconomic before overhead
- Operating cash outflow is smaller than net loss, suggesting some non-cash loss components
BFNH Stock Risks: Bioforce Nanosciences Holdings, Inc.. Investment Risks
- Negative stockholders' equity of -$499.9K represents technical insolvency
- Revenue of only $17.8K annually is insufficient to support operations or debt service
- Operating losses of -$372.2K with net losses of -$1.2M indicate business model failure
- Negative operating cash flow of -$54.2K shows cash burn despite minimal operations
- Current ratio of 0.00x indicates severe liquidity crisis with inability to meet obligations
- No insider activity in 90 days suggests management disengagement
- Extreme negative margins (-2093.7% operating, -6601.1% net) demonstrate complete operational failure
- Revenue base is immaterial relative to the cost structure, producing extreme negative operating and net margins
- Balance sheet is severely impaired with negative stockholders equity and minimal cash resources
- Liquidity is effectively exhausted, raising substantial going-concern and financing risk
Key Metrics to Watch
- Whether company remains operating or files for bankruptcy
- Any revenue recovery toward minimum viable operating levels
- Stockholders' equity trend and whether insolvency worsens
- Quarterly revenue growth and gross margin improvement
- Cash balance, operating cash flow, and any recapitalization or liability restructuring
Bioforce Nanosciences Holdings, Inc.. (BFNH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BFNH Profit Margin, ROE & Profitability Analysis
BFNH vs Industrial Sector: How Bioforce Nanosciences Holdings, Inc.. Compares
How Bioforce Nanosciences Holdings, Inc.. compares to Industrial sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Bioforce Nanosciences Holdings, Inc.. Stock Overvalued? BFNH Valuation Analysis 2026
Based on fundamental analysis, Bioforce Nanosciences Holdings, Inc.. has mixed fundamental signals relative to the Industrial sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Bioforce Nanosciences Holdings, Inc.. Balance Sheet: BFNH Debt, Cash & Liquidity
BFNH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Bioforce Nanosciences Holdings, Inc..'s revenue has shown modest growth of 9% over the 5-year period. The most recent EPS of $-0.02 indicates the company is currently unprofitable.
BFNH Revenue Growth, EPS Growth & YoY Performance
BFNH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2020 | $6.0K | -$6.3K | N/A |
| Q2 2020 | $6.0K | -$7.2K | N/A |
| Q1 2020 | $5.9K | -$12.9K | N/A |
| Q3 2019 | $5.5K | -$6.3K | N/A |
| Q2 2019 | $5.1K | -$7.2K | N/A |
| Q1 2019 | $5.9K | -$12.9K | N/A |
| Q3 2018 | $5.5K | -$2.2K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Bioforce Nanosciences Holdings, Inc.. Dividends, Buybacks & Capital Allocation
BFNH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Bioforce Nanosciences Holdings, Inc.. (CIK: 0001310488)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BFNH
What is the AI rating for BFNH?
Bioforce Nanosciences Holdings, Inc.. (BFNH) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 96% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BFNH's key strengths?
Claude: Minimal cash burn relative to asset base in current period. Positive gross margin of 24.5% indicates some pricing power on limited sales. ChatGPT: The company is still generating some revenue, indicating limited ongoing commercial activity. Gross profit is positive, showing the core product/service is not completely uneconomic before overhead.
What are the risks of investing in BFNH?
Claude: Negative stockholders' equity of -$499.9K represents technical insolvency. Revenue of only $17.8K annually is insufficient to support operations or debt service. ChatGPT: Revenue base is immaterial relative to the cost structure, producing extreme negative operating and net margins. Balance sheet is severely impaired with negative stockholders equity and minimal cash resources.
What is BFNH's revenue and growth?
Bioforce Nanosciences Holdings, Inc.. reported revenue of $17.8K.
Does BFNH pay dividends?
Bioforce Nanosciences Holdings, Inc.. does not currently pay dividends.
Where can I find BFNH SEC filings?
Official SEC filings for Bioforce Nanosciences Holdings, Inc.. (CIK: 0001310488) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BFNH's EPS?
Bioforce Nanosciences Holdings, Inc.. has a diluted EPS of $-0.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BFNH a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Bioforce Nanosciences Holdings, Inc.. has a STRONG SELL rating with 96% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BFNH stock overvalued or undervalued?
Valuation metrics for BFNH: ROE of N/A (sector avg: 15%), net margin of -6,601.1% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy BFNH stock in 2026?
Our dual AI analysis gives Bioforce Nanosciences Holdings, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BFNH's free cash flow?
Bioforce Nanosciences Holdings, Inc..'s operating cash flow is $-54.2K, with capital expenditures of N/A. FCF margin is -305.1%.
How does BFNH compare to other Industrial stocks?
Vs Industrial sector averages: Net margin -6,601.1% (avg: 10%), ROE N/A (avg: 15%), current ratio 0.00 (avg: 1.8).